| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Biomedical Graduate Program [M. S. G., H. K. K.], Departments of Radiation Oncology [C. J. K., S. M. E., W. T. J.], Pathology and Laboratory Medicine [C. H. P., J. S. M.], and Medicine [W. M. F. L.], Cancer Center [J. S. M., W. M. F. L.], and Flow Cytometry and Cell Sorting Facility [C. H. P., J. S. M.], University of Pennsylvania, Philadelphia, Pennsylvania 19104; Department of Microbiology and Immunology and Cancer Center Immunology Program, University of Rochester, Rochester, New York 14642 [J. L., E. M. L.]; and The Wistar Institute, Philadelphia, Pennsylvania 19104 [G. T., W. M. F. L.].
The role of angiogenesis inhibition in the antitumor activity of recombinant murine interleukin 12 (rmIL-12) was studied in K1735 murine melanomas, the growth of which is rapidly and markedly suppressed by rmIL-12 treatment. On the basis of the prediction that tumor ischemia should result from therapeutic angiogenesis inhibition, tumor cell hypoxia was evaluated as a marker of ischemia using the EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] approach. This method measures intracellular binding of the nitroimidazole EF5, which covalently binds to cellular macromolecules selectively under hypoxic conditions. Whereas 1 week of rmIL-12 treatment effectively inhibited K1735 cell-induced angiogenesis in Matrigel neovascularization assays, 2 weeks of treatment were needed before severe tumor cell hypoxia was detected in K1735 tumors. The hypoxia that developed was regional and localized to tumor areas distant from blood vessels. The great majority of severely hypoxic tumor cells were apoptotic, and in vitro studies indicated that the degree of hypoxia present within treated tumors was sufficient to trigger K1735 apoptosis. Tumor cell apoptosis was also prevalent in the first week of rmIL-12 treatment when few cells were hypoxic. In vitro studies indicated that this non-hypoxia-related apoptosis was induced directly by IFN-
produced in response to rmIL-12 administration. These studies reveal that rmIL-12 controls K1735 tumors initially by IFN--induced apoptosis and later by hypoxia-induced apoptosis. They also establish hypoxia as an expected result of tumor angiogenesis inhibition and a mediator of its therapeutic effect.
This article has been cited by other articles:
|
|
 |
|
  J. H. Tsai and W. M.F. Lee Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic Therapy Mol. Cancer Res., March 1, 2009; 7(3): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-W. Yang, B. Shu, Y. Zhu, and H.-T. Yang E2F6 Inhibits Cobalt Chloride-Mimetic Hypoxia-induced Apoptosis through E2F1 Mol. Biol. Cell, September 1, 2008; 19(9): 3691 - 3700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy Cancer Res., June 15, 2008; 68(12): 4810 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pisati, M. Belicchi, F. Acerbi, C. Marchesi, C. Giussani, M. Gavina, S. Javerzat, M. Hagedorn, G. Carrabba, V. Lucini, et al. Effect of Human Skin-Derived Stem Cells on Vessel Architecture, Tumor Growth, and Tumor Invasion in Brain Tumor Animal Models Cancer Res., April 1, 2007; 67(7): 3054 - 3063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Dace, P. W. Chen, H. Alizadeh, and J. Y. Niederkorn Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner J. Leukoc. Biol., February 1, 2007; 81(2): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Murphy, S. Makonnen, W. Lassoued, M. D. Feldman, C. Carter, and W. M.F. Lee Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006) Am. J. Pathol., November 1, 2006; 169(5): 1875 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Ziemer, W. M. F. Lee, S. A. Vinogradov, C. Sehgal, and D. F. Wilson Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence J Appl Physiol, April 1, 2005; 98(4): 1503 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gee, S. Makonnen, K. al-Kofahi, B. Roysam, F. Payvandi, H.-W. Man, G. W. Muller, and W. M. F. Lee Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition Cancer Res., December 1, 2003; 63(23): 8073 - 8078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mitola, M. Strasly, M. Prato, P. Ghia, and F. Bussolino IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production J. Immunol., October 1, 2003; 171(7): 3725 - 3733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. A. Portielje, C. H. J. Lamers, W. H. J. Kruit, A. Sparreboom, R. L. H. Bolhuis, G. Stoter, C. Huber, and J. W. Gratama Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-{gamma}, Tumor Necrosis Factor-{alpha}, IL-6, and IL-8 Responses Clin. Cancer Res., January 1, 2003; 9(1): 76 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gee, W. N. Procopio, S. Makonnen, M. D. Feldman, N. M. Yeilding, and W. M. F. Lee Tumor Vessel Development and Maturation Impose Limits on the Effectiveness of Anti-Vascular Therapy Am. J. Pathol., January 1, 2003; 162(1): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Hill, T. F. Conway Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease Cancer Res., December 15, 2002; 62(24): 7254 - 7263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Segal, N. C. Lee, Y. L. Tsung, J. A. Norton, and K. Tsung The Role of IFN-{gamma} in Rejection of Established Tumors by IL-12 : Source of Production and Target Cancer Res., August 15, 2002; 62(16): 4696 - 4703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Y. Crowe, M. J. Smyth, and D. I. Godfrey A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas J. Exp. Med., July 1, 2002; 196(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Smyth, N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita, and D. I. Godfrey Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide Blood, February 15, 2002; 99(4): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lee, D. C. Kim, M. S. Gee, H. M. Saunders, C. M. Sehgal, M. D. Feldman, S. R. Ross, and W. M. F. Lee Interleukin-12 Inhibits Angiogenesis and Growth of Transplanted but not in Situ Mouse Mammary Tumor Virus-induced Mammary Carcinomas Cancer Res., February 1, 2002; 62(3): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saio, S. Radoja, M. Marino, and A. B. Frey Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide J. Immunol., November 15, 2001; 167(10): 5583 - 5593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hunter, D. Yu, M. Gee, C. V. Ngo, C. Sevignani, M. Goldschmidt, T. V. Golovkina, S. Evans, W. F. Lee, and A. Thomas-Tikhonenko Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis J. Immunol., May 15, 2001; 166(10): 5878 - 5881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations Cancer Res., April 1, 2001; 61(7): 2974 - 2982. [Abstract] [Full Text]
|
|
|
|
|
|
M. Strasly, F. Cavallo, M. Geuna, S. Mitola, M. P. Colombo, G. Forni, and F. Bussolino IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk J. Immunol., March 15, 2001; 166(6): 3890 - 3899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Beatty and Y. Paterson IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}} J. Immunol., February 15, 2001; 166(4): 2276 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells Cancer Res., December 1, 2000; 60(23): 6696 - 6703. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. H. Shoemaker Genetic and Epigenetic Factors in Anticancer Drug Resistance J Natl Cancer Inst, January 5, 2000; 92(1): 4 - 5. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
